Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance-MedSci.cn

Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance

Liu, FB; Zhao, QS; Su, YW; Lv, J; Gai, YQ; Liu, S; Lin, H; Wang, Y; Wang, G

Wang, Y (通讯作者)，First Hosp Jilin Univ, Dept Pediat Hematol & Oncol, 71 Xinmin St, Changchun, Jilin, Peoples R China.;Wang, G (通讯作者)，Jilin Univ, Sch Life Sci, 2699 Qianjin St, Changchun, Jilin, Peoples R China.

Abstract

Acute myeloid leukemia (AML) remains a clinical challenge. Venetoclax is an effective Bcl-2 selective inhibitor approved by the U.S. Food and Drug Adm......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance

科室

工具

服务